Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus (NCT01171976), a randomized phase 3 study. The primary outcome is Visual Acuity of the Study Eye: Average Change From Baseline to Month 1 Through Month 12.

2. Clinical Question

3. Trial Design

This was a randomized, single-masked, multicenter, controlled Phase IIIb trial with a parallel-group design. The official title describes a two-year study of ranibizumab 0.5 mg treatment algorithms in patients with macular edema and visual impairment secondary to diabetes mellitus. The registry lists planned enrollment of 373 participants and a completed study. The recorded start was 2010-09, and primary completion was 2013-04.

Participants were assigned to one of three groups: treat-and-extend ranibizumab 0.5 mg with laser, treat-and-extend ranibizumab 0.5 mg alone, or ranibizumab 0.5 mg as needed. The record says the laser group received ranibizumab on Day 1, followed by a phase of monthly injections, and that laser was applied on Day 1. It could be administered again according to ETDRS criteria at a visit with ranibizumab treatment. The arm description ends before the full criteria are stated, so the subsequent schedule and decision rules cannot be reconstructed. The other treat-and-extend arm is described only as ranibizumab injection therapy, while the as-needed arm was treated according to disease signs and symptoms.

Randomization and a parallel-group structure support comparisons between assigned regimens, but the record does not report the allocation sequence, concealment procedures, masking details, or the number of centers. It identifies the study as single-masked without specifying who was masked. The record also does not report adherence, treatment exposure, withdrawals, or the actual number analyzed in each group for the primary endpoint. The planned enrollment should therefore not be treated as the observed analysis sample.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Antimicrobial eye drops were dispensed at each study visit (PRN ranibizumab) or at visits with scheduled injections (TE ranibizumab + laser or TE ranibizumab alone).

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Analyzed set included all randomized patients who received at least one application of study treatment and had at least one post baseline efficacy assessment. If missing values occurred without a subsequent observed value, the last observed value was carried forward to subsequent scheduled visits by means of a last observation carried forward.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: The Randomized Set comprised all randomized patients, ie those given a randomization number.

6. Primary Endpoint

The registry lists the primary outcome as Visual Acuity of the Study Eye: Average Change From Baseline to Month 1 Through Month 12, measured over Baseline to Month 12.

The primary endpoint was the average change from baseline in study-eye visual acuity from Month 1 through Month 12. Visual acuity was assessed at each study visit using best correction determined from protocol refraction. Best-corrected visual acuity measurements were taken with the participant sitting, using ETDRS-like testing charts at a starting distance of 4 meters. The measure is reported in letters.

Visual acuity is a continuous outcome, so the endpoint can describe the average change in visual function across participants rather than only whether each person crossed a predefined threshold. Repeated assessments over the stated interval can represent the course of the measured outcome across visits. These are general properties of continuous and repeated measurements; they do not establish the size or direction of a treatment effect in this trial.

The registry record does not include numerical arm-specific averages, a measure of uncertainty, or a reported statistical comparison for the primary endpoint. It therefore does not show the magnitude or precision of any between-group difference. The study’s stated objective was to compare the two treat-and-extend approaches with as-needed ranibizumab, but the objective alone is not evidence that either regimen produced greater improvement.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The following explanations describe general statistical concepts and how they relate to the registry information. They do not substitute for an analysis plan or results, neither of which is fully reported in the registry record.

What does an average change measure?

For a continuous outcome such as visual acuity measured in letters, an average change summarizes the typical direction and size of change across the participants included in an analysis. It does not show every participant’s response, and an average can conceal substantial variation. The primary endpoint averages change over visits from Month 1 through Month 12, while other listed visual-acuity outcomes refer to specific time points or categorized changes. Those are distinct summaries and should not be treated as interchangeable.

The record identifies the primary outcome’s dispersion as standard deviation. In general, a standard deviation describes how spread out individual measurements are around their mean; it is not the same as uncertainty in the estimated mean. A confidence interval, if reported, would describe uncertainty around an estimate under the assumptions of the analysis. No confidence interval or standard error for the primary endpoint is reported in the registry record.

What would a between-group comparison tell readers?

In general, a randomized comparison estimates how outcomes differed between the assigned groups, subject to the analysis population, missing data, and other assumptions. A group’s change from baseline on its own does not answer whether it changed more or less than another group. That requires a between-group contrast and an estimate of its uncertainty. The registry gives the trial’s comparison objective but does not report the primary outcome contrast or its uncertainty, so the comparative question cannot be answered numerically from the record.

A p-value, when reported, summarizes how compatible the data are with a specified null model under the analysis assumptions. It is not a measure of the size or clinical importance of an effect. The registry record does not report a primary-outcome p-value or analysis entry. It would therefore be inappropriate to infer statistical significance, or its absence, from the study objective or from the fact that the study was completed.

Why do analysis populations matter?

The record defines the primary analysis population as randomized participants who received at least one application of study treatment and had at least one post-baseline efficacy assessment. In general, excluding participants who do not meet such criteria can make an analysis differ from one that includes everyone as randomized. The definition alone does not show how many participants were included or excluded, whether exclusions differed across groups, or how those decisions affected the estimates. Those counts and details are not reported in the registry record.

How should repeated measurements be understood?

Visual acuity was measured at every study visit, and the primary outcome summarizes average change across a sequence of visits. Repeated measurements from the same participant are related rather than independent. General methods for longitudinal outcomes account for that dependence or define a summary across visits. The registry identifies the average-change endpoint and mentions a carry-forward procedure for a stated missing-data situation, but does not report the full statistical model, covariance assumptions, or other analysis details. These aspects of the analysis plan are not reported in the registry record.

What can planning illustrations show?

In general, sample-size calculations illustrate how many participants might be needed under specified assumptions about the effect to detect, significance level, allocation, and statistical model. They are planning exercises, not evidence about what happened in a completed trial. The record describes a planning illustration based on the observed effect, with a two-sided significance level of 0.05, equal allocation, and a normal approximation; the effect to detect is stated as a fraction of the observed effect. It also distinguishes illustrations expressed as participants per arm from those expressed as total events for time-to-event outcomes. These assumptions should not be mistaken for the trial’s own design justification, which is not reported in the registry record, or for observed power. The registry information does not provide the trial’s sample-size justification.

There is no basis in the registry record for reconstructing additional analyses or determining whether an analysis plan specified adjustments, sensitivity analyses, or interim monitoring. Such methods can affect interpretation, but their presence should not be assumed. The result-level information needed to evaluate estimates, uncertainty, and model fit is also not reported. Thus, the general concepts explain what statistical information would ordinarily help readers assess a randomized trial, while the actual comparative findings remain unquantified in this record.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists a primary visual-acuity outcome and secondary outcomes covering repeated or time-specific visual-acuity changes, categorized visual-acuity changes, central subfield thickness, and VFQ-25 total score. Considering multiple outcomes or time points can raise a multiplicity issue: when many statistical tests are conducted, the chance of at least one apparently unusual result can increase. General approaches include prespecifying a hierarchy or adjusting inference, but the registry record does not report whether any such approach was planned or used. It also does not report outcome-specific statistical tests or results. The record notes that the primary outcome has several categories or time points and was not reduced to one comparison.

For missing data, the primary population description says that when missing values occurred without a subsequent observed value, the last observed value was carried forward to subsequent scheduled visits. The description is truncated after that statement, and fuller rules for missing observations are not reported in the registry record. The number of missing measurements, reasons for missingness, and any sensitivity analyses are also not reported. In general, carrying an earlier observation forward makes an assumption about later unobserved values; whether that assumption is suitable depends on the setting and the pattern of missingness. The record does not provide enough detail to evaluate its impact.

The analysis population includes randomized participants who received at least one application of treatment and had at least one post-baseline efficacy assessment. The record does not report how many participants met this definition in each group or how it relates to all randomized participants. It lists zero analyses, which means no analysis entries are available in the registry record; it does not establish that investigators performed no analyses. Adjustment for baseline values, handling of protocol deviations, subgroup analyses, and interim analyses are not reported in the registry record.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 1.5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: myocardial infarction (3.2%), cerebrovascular accident (2.5%), pneumonia (2.4%), prostate cancer (1.7%), acute myocardial infarction (1.6%).

The registry reports serious adverse events for the three treatment groups. For treat-and-extend ranibizumab 0.5 mg and laser, 34 of 126 participants were recorded as affected by serious adverse events. For treat-and-extend ranibizumab 0.5 mg alone, the figures were 29 of 126. For as-needed ranibizumab 0.5 mg, they were 26 of 118. These are counts of participants, not counts of individual events; a participant may experience more than one event. The registry also lists other adverse events separately: 98 of 126, 101 of 126, and 78 of 118, respectively. The record does not define the distinction between these categories in the available information.

The serious-event terms listed with percentages are myocardial infarction (3.2%), cerebrovascular accident (2.5%), pneumonia (2.4%), prostate cancer (1.7%), acute myocardial infarction (1.6%), and atrial fibrillation (1.6%). These percentages should be read as registry-reported figures; the record does not state their group-specific breakdown or provide further details about event timing, recurrence, or attribution. Their appearance in a trial safety listing does not establish that a study treatment caused an event.

Deaths are not reported in the registry record. The available figures do not supply a complete assessment of comparative safety or enough context to determine whether group differences are meaningful. They should be interpreted as reported event counts rather than as proof for or against a causal relationship.

12. What the Result Does, and Does Not, Mean

The registry record establishes that this was a randomized, single-masked, multicenter, controlled Phase IIIb study comparing three ranibizumab treatment approaches in diabetic macular edema. It identifies average change in study-eye visual acuity through Month 12 as the primary outcome and describes how visual acuity was measured. It also records secondary outcome domains and selected adverse-event counts. These details clarify the research question and the kinds of outcomes considered.

What the record does not establish is the magnitude, direction, or precision of the primary comparison. No numerical primary-outcome results, confidence intervals, or statistical tests are reported. As a result, the information does not show whether any group had greater average visual-acuity improvement, how variable participant outcomes were, or how compatible the data were with different possible between-group effects. A stated aim to demonstrate superiority is not a finding that superiority was demonstrated.

The safety counts are descriptive and do not establish causation. They also do not, on their own, resolve comparative safety because the record does not report a full analysis, timing, or attribution. Likewise, the listed secondary outcomes do not support conclusions about visual acuity at Month 24, retinal thickness, or questionnaire scores without their estimates and uncertainty.

In general, results from a randomized trial apply most directly to the studied population and treatment conditions, and interpretation depends on the analysis methods and completeness of follow-up. Here, important details about the treatment algorithms, missing data, and statistical analyses are not fully reported. The record therefore supports a careful account of the design and available descriptive safety information, but not a conclusion about comparative clinical effects. It should not be read as evidence that a regimen does or does not work.

13. Why This Trial Matters Statistically

Statistically, the trial poses a comparison among two treat-and-extend strategies and an as-needed regimen, with visual acuity as a continuous primary outcome measured repeatedly over time. That combination makes the estimand—the precise treatment contrast and population the analysis is intended to describe—important. The registry names the outcome and gives an analysis-population definition, but does not provide the numerical contrast or enough analysis detail to determine exactly how repeated observations contributed to the estimate.

The study also illustrates why a trial’s objective and its results must be distinguished. The stated purpose concerns potential superiority, while the registry record contains no primary-outcome analysis entries. Without estimates and uncertainty, readers cannot judge the size or precision of a difference. Reporting the measurement method and outcome schedule is useful, but it cannot replace those results.

Multiplicity and missing data are relevant because the record lists several outcome domains and time points, and describes carrying forward the last observed value for a specified missing-data situation. General statistical practice treats these choices as part of the interpretation rather than as administrative details: outcome selection affects which claims are supported, and assumptions about missing values can influence estimates. The registry record does not report enough information to assess these choices fully.

Finally, the serious adverse-event counts illustrate the distinction between descriptive reporting and causal inference. Counts can help characterize what was recorded in each group, but by themselves they do not attribute events to treatment or establish a comparative safety effect. The record is therefore useful for identifying the design, endpoint, missing-data statement, and selected safety information, while its lack of outcome analyses sharply limits statistical conclusions.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The most important limitation of the registry information is the absence of numerical results for the primary visual-acuity endpoint. There are no reported group estimates, between-group contrasts, uncertainty intervals, or test results. The record lists zero analyses, so comparative efficacy cannot be evaluated from the available registry entries.

Descriptions of the interventions are incomplete. In particular, the treat-and-extend arm with laser description ends before all later treatment criteria are stated. The record does not give the full treatment algorithms, the allocation method, details of who was masked, or the number of participating centers. These omissions constrain interpretation of how closely the treatments can be characterized.

The primary analysis population is defined, but its group-specific size is not reported. The record also does not give participant flow, missing-measurement counts, reasons for missingness, or complete rules for handling missing outcomes. The carry-forward statement is truncated, and no sensitivity analyses are reported. The outcome list includes multiple domains and time points, while multiplicity procedures and the statistical plan are not reported in the registry record.

Safety information is limited to selected counts and serious-event terms. The record does not report deaths, group-specific breakdowns for the listed terms, event timing, or attribution. These limitations mean the available safety information is descriptive and incomplete. The study’s sample-size justification, interim analyses, and detailed analysis plan are not reported in the registry record. These absences should not be filled by assumptions about common trial practice.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus — NCT01171976.
• Registry record last updated 2014-09-15; status last verified 2014-09.
• Results first posted 2014-09-15.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The record describes a completed, randomized, single-masked, multicenter, parallel-group Phase IIIb trial of ranibizumab 0.5 mg in patients with macular edema and visual impairment secondary to diabetes mellitus. Planned enrollment was 373. The groups used treat-and-extend ranibizumab with laser, treat-and-extend ranibizumab alone, or ranibizumab as needed.

The primary outcome was average change in study-eye visual acuity from baseline through Month 12, measured in letters. Secondary outcomes included visual acuity, central subfield thickness, and VFQ-25 total score. The registry record lists serious adverse-event counts by group and selected serious-event terms.

Numerical primary-outcome results and statistical analyses are not reported in the registry record. The record also does not report the full statistical plan, complete missing-data rules, or the study’s sample-size justification.